Product Description
Aceclidine has been marketed in Europe but has not been used clinically in the United States. It is used in the treatment of open-angle glaucoma and is a parasympathomimetic agent.
Mechanisms of Action: mAChR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Ophthalmic
FDA Designation: *
Approval Status: Approved
Approved Countries: Germany | Greece | Italy | Peru | Portugal
Approved Indications: None
Company: LENZ Therapeutics, Inc
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Miosis|Presbyopia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06045299 |
JX07001 | P3 |
Completed |
Presbyopia|Miosis |
2024-08-19 |
2025-03-04 |
Primary Endpoints |
|
NCT06270030 |
JX07002 | P1 |
Completed |
Presbyopia |
2024-04-10 |
2025-08-27 |
Primary Endpoints |
|
CTR20240460 |
CTR20240460 | P1 |
Completed |
Presbyopia |
2024-04-10 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |